Marc‐Oliver Grimm
YOU?
Author Swipe
View article: Effects of Prior Local Therapy by Radical Prostatectomy or Radiotherapy on the Efficacy and Quality of Life of Patients Treated With Darolutamide in ARAMIS
Effects of Prior Local Therapy by Radical Prostatectomy or Radiotherapy on the Efficacy and Quality of Life of Patients Treated With Darolutamide in ARAMIS Open
Background Darolutamide plus androgen‐deprivation therapy (ADT) improved metastasis‐free survival (MFS) by 2 years and reduced the risk of death by 31% in nonmetastatic castration‐resistant prostate cancer (nmCRPC) in ARAMIS. Prior local t…
View article: Profiling autoantibodies at baseline and during immune checkpoint inhibitor therapy of renal cell carcinoma patients—exploratory results from TITAN-RCC
Profiling autoantibodies at baseline and during immune checkpoint inhibitor therapy of renal cell carcinoma patients—exploratory results from TITAN-RCC Open
Our findings revealed that neither the presence of autoantibodies at baseline nor the new occurrence of the majority of investigated autoantibodies during ICI therapy did predict irAE development in RCC patients. However, the appearance of…
View article: Artificial Intelligence-Assisted Biparametric MRI for Detecting Prostate Cancer—A Comparative Multireader Multicase Accuracy Study
Artificial Intelligence-Assisted Biparametric MRI for Detecting Prostate Cancer—A Comparative Multireader Multicase Accuracy Study Open
Objectives: To evaluate the diagnostic accuracy of AI-assisted biparametric MRI (AI-bpMRI) in detecting prostate cancer (PCa) as a possible replacement for multiparametric MRI (mpMRI) depending on readers’ experience. Methods: This fully c…
View article: Postprogression Survival of Patients with Metastatic Hormone-sensitive Prostate Cancer who Received Darolutamide or Placebo in Combination with Docetaxel and Androgen Deprivation Therapy: Post Hoc Analysis of the Phase 3 ARASENS Trial
Postprogression Survival of Patients with Metastatic Hormone-sensitive Prostate Cancer who Received Darolutamide or Placebo in Combination with Docetaxel and Androgen Deprivation Therapy: Post Hoc Analysis of the Phase 3 ARASENS Trial Open
For ARPI-naïve patients who did not receive darolutamide in ARASENS, postprogression survival was longer with subsequent ARPI versus taxane treatment, but OS remained shorter in comparison to the darolutamide group. Decisions on postprogre…
View article: IS THERE A ROLE OF THE ENDOGENOUS NEUROPEPTIDE OXYTOCIN IN THE PATHOPHYSIOLOGY OF ERECTILE DYSFUNCTION (ED)?
IS THERE A ROLE OF THE ENDOGENOUS NEUROPEPTIDE OXYTOCIN IN THE PATHOPHYSIOLOGY OF ERECTILE DYSFUNCTION (ED)? Open
Objectives The pro-erectile effects of the activation of dopaminergic receptors in the brain, for example, by the receptor agonist apomorphine, involves oxytocinergic pathways descending from the hypothalamus to spinal centers. In male rat…
View article: Correction: Optimal length and temporal resolution of dynamic contrast-enhanced MR imaging for the differentiation between prostate cancer and normal peripheral zone tissue
Correction: Optimal length and temporal resolution of dynamic contrast-enhanced MR imaging for the differentiation between prostate cancer and normal peripheral zone tissue Open
[This corrects the article DOI: 10.1371/journal.pone.0287651.].
View article: Open versus robotic-assisted partial nephrectomy in patients with intermediate/high-complexity kidney tumours: final results of the randomised, controlled, open-label, multicentre trial OpeRa
Open versus robotic-assisted partial nephrectomy in patients with intermediate/high-complexity kidney tumours: final results of the randomised, controlled, open-label, multicentre trial OpeRa Open
There was no statistically significant difference in the 30-day complication rate between RAPN and OPN in this underpowered trial. Few high-grade complications occurred over the whole cohort with intermediate/high-complexity tumours. Despi…
View article: Comprehensive genomic characterization of early-stage bladder cancer
Comprehensive genomic characterization of early-stage bladder cancer Open
Understanding the molecular landscape of nonmuscle-invasive bladder cancer (NMIBC) is essential to improve risk assessment and treatment regimens. We performed a comprehensive genomic analysis of patients with NMIBC using whole-exome seque…
View article: Complications of Tumor Nephrectomy with and Without Tumor Thrombus in the Vena Cava, Recorded with the Clavien–Dindo Classification: A Matched-Pair Analysis
Complications of Tumor Nephrectomy with and Without Tumor Thrombus in the Vena Cava, Recorded with the Clavien–Dindo Classification: A Matched-Pair Analysis Open
Background/Objectives: Radical nephrectomy (RN) with inferior vena cava thrombectomy (IVCT) is indicated for the curative management of renal cell carcinoma (RCC) with tumor thrombus (TT). In the literature, any direct comparison of compli…
View article: Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial
Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial Open
PURPOSE CheckMate 914 is a two-part, randomized phase III trial evaluating adjuvant nivolumab plus ipilimumab (part A) or adjuvant nivolumab monotherapy (part B) versus placebo in mutually exclusive populations of patients with localized r…
View article: 8 Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: 8-year follow-up with analyses in favorable risk patients from the phase 3 CheckMate 214 trial
8 Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: 8-year follow-up with analyses in favorable risk patients from the phase 3 CheckMate 214 trial Open
Background First-line nivolumab plus ipilimumab (NIVO+IPI) has provided substantial long-term survival benefits over sunitinib (SUN) in patients with advanced renal cell carcinoma (aRCC) in CheckMate 214. With a median follow-up of 8 years…
View article: Reasonability of Frequent Laboratory Analyses during Therapy with Nivolumab and Nivolumab+Ipilimumab in Patients with Advanced or Metastatic Renal Cell Carcinoma during the Phase 2 Clinical Trial TITAN-RCC
Reasonability of Frequent Laboratory Analyses during Therapy with Nivolumab and Nivolumab+Ipilimumab in Patients with Advanced or Metastatic Renal Cell Carcinoma during the Phase 2 Clinical Trial TITAN-RCC Open
In clinical trials, laboratory values are assessed with high frequency. This can be stressful for patients, resource intensive, and difficult to implement, for example in office-based settings. In the prospective, multicentre phase 2 TITAN…
View article: Association between neutrophil-to-eosinophil ratio and efficacy outcomes with avelumab plus axitinib or sunitinib in patients with advanced renal cell carcinoma: post hoc analyses from the JAVELIN Renal 101 trial
Association between neutrophil-to-eosinophil ratio and efficacy outcomes with avelumab plus axitinib or sunitinib in patients with advanced renal cell carcinoma: post hoc analyses from the JAVELIN Renal 101 trial Open
Objective We report post hoc analyses of efficacy with first-line avelumab plus axitinib or sunitinib according to baseline neutrophil-to-eosinophil ratio (NER) in patients with advanced renal cell carcinoma (aRCC) from the JAVELIN Renal 1…
View article: Treatment patterns and clinical outcomes in metastatic urothelial carcinoma: a German retrospective real-world analysis
Treatment patterns and clinical outcomes in metastatic urothelial carcinoma: a German retrospective real-world analysis Open
Aim: This study assessed real-world treatment in patients with metastatic urothelial carcinoma (mUC) in Germany. Materials & methods: Patients diagnosed with mUC from 2015 to 2019 were identified in two claims databases: AOK PLUS and GWQ. …
View article: Healthcare resource utilization and associated costs in patients with metastatic urothelial carcinoma: a real-world analysis using German claims data
Healthcare resource utilization and associated costs in patients with metastatic urothelial carcinoma: a real-world analysis using German claims data Open
The study shows that mUC is associated with significant HCRU and costs across different types of 1 L systemic therapy.
View article: PAE planning: Radiation exposure and image quality of CT and CBCT
PAE planning: Radiation exposure and image quality of CT and CBCT Open
In our study preprocedural CT had lower organ doses and better image quality comparedd with CBCT and should be considered for the correct identification of prostatic arteries.
View article: Corrigendum to “Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score” [Eur. Urol. 83(5) (2024) 432–440]
Corrigendum to “Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score” [Eur. Urol. 83(5) (2024) 432–440] Open
International audience
View article: 28P 3-year follow-up analysis of disease-free survival in CheckMate 274 by PD-L1 expression using tumor cell and combined positive scoring algorithms
28P 3-year follow-up analysis of disease-free survival in CheckMate 274 by PD-L1 expression using tumor cell and combined positive scoring algorithms Open
CheckMate 274 met the primary endpoints of improved disease-free survival (DFS) with nivolumab (NIVO) v placebo (PBO) both in the intent-to-treat (ITT) population and in patients (pts) with programmed death-ligand 1 (PD-L1) expression ≥1% …
View article: A Pooled Analysis of 3 Phase II Trials of Salvage Nivolumab/Ipilimumab After Nivolumab in Renal Cell Carcinoma
A Pooled Analysis of 3 Phase II Trials of Salvage Nivolumab/Ipilimumab After Nivolumab in Renal Cell Carcinoma Open
Background Nivolumab plus ipilimumab has demonstrated improved survival for treatment-naïve advanced clear cell renal cell carcinoma (RCC). A series of clinical trials evaluated the effect of salvage nivolumab plus ipilimumab in patients w…
View article: Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial
Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial Open
Data on the effects of prior cytoreductive nephrectomy (CN) in patients with renal cell carcinoma (RCC) with synchronous metastases (M1 disease) before immune checkpoint inhibitor (ICI) treatment are limited. In this post hoc analysis of t…
View article: Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice
Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice Open
The JAVELIN Bladder 100 phase III trial led to the incorporation of avelumab first-line (1L) maintenance treatment into international guidelines as a standard of care for patients with advanced urothelial carcinoma (UC) without progression…